Ocular Therapeutix, Inc.

November 21, 2017 Ocular Therapeautix, Inc. and four top executives are facing a securities lawsuit filed in August that claims the parties misled investors regarding the pending approval of DEXTENZA, a new medicine designed to treat post-surgical eye pain.

July 7, 2017 Ocular Therapeutix, Inc. and four executives are facing a stockholder’s claims that they misled investors about the quality and future success of Dextenza – a drug currently undergoing clinical trials for the treatment of certain eye conditions.